Major alcohol stocks are down as much as 80% over five years, vastly underperforming the S&P 500. This is not a temporary dip but a secular decline driven by a confluence of factors: cannabis legalization, the appetite-suppressing effects of weight-loss drugs like Ozempic, and general health consciousness, creating a potential contrarian investment opportunity.

The widespread adoption of weight-loss drugs is reducing demand for products like wine bottles and beer cans. This introduces a significant, unforeseen secular risk to packaging companies, a sector traditionally considered a safe bet by credit investors who often focus only on coupon payments and credit ratings.

Chef David Chang identifies that Gen Z's reduced alcohol consumption is a major financial threat to the restaurant industry. Traditionally high-margin beverage sales have subsidized food costs, but this model is breaking down. As a result, restaurants face a dual pressure of rising labor costs and shrinking beverage revenue, forcing a difficult choice between raising food prices or facing insolvency.

A world-famous chef claims the mid-tier restaurant business is "over." Patrons on drugs like Ozempic eat less, and younger generations drink less alcohol, drastically reducing average check sizes. This makes the economics of a $75-per-person establishment unsustainable, leaving only high-end and fast-casual options viable.

While mass-market wine sales are in a secular decline, the fine wine category is behaving like a luxury good. Similar to Swiss watches in a digital era, top-tier wines are retaining value as status symbols, creating a stark bifurcation in the overall market.

A surprising driver of Fruitist's success is the Ozempic effect. GLP-1 drug users consume more fruit but are averse to "surprises" in taste or texture. This creates demand for branded, highly consistent produce, allowing companies like Fruitist to command a premium price from this growing consumer segment.

The widespread adoption of GLP-1 drugs for obesity, projected to reach 25 million U.S. users, will significantly reduce food, soda, and alcohol consumption. This presents a material, long-term revenue threat to consumer-facing industries like fast food, snack companies, and even casinos, forcing investors in those sectors to adjust their models.

The widespread adoption of GLP-1 therapies is projected to decrease total U.S. calorie consumption by 1.6% by 2035. This second-order effect will create significant disruption and headwinds for industries reliant on consumer food purchasing, including the CPG, retail, and restaurant sectors.

The global decline in wine sales faces a new headwind from the rise of GLP-1 drugs. Analysts worry that as these medications reduce users' desire to eat, they also diminish the desire to drink alcohol, further depressing a market already struggling with demographic and cultural shifts.